Novartis Gets Priority Review for Kidney Disease Treatment
By Ben Glickman
Novartis said it received priority review for Fabhalta as a potential treatment for IgA nephropathy, a rare kidney disease.
The pharmaceutical company said Monday that its submission to the U.S. Food and Drug Administration for potential accelerated approval of its treatment had been accepted. The company's IgA nephropathy treatment has received priority review, the company said, which means regulators are aiming to act on the application within six months.
The company's treatment Fabhalta is being evaluated in a Phase 3 trial. An interim analysis found a clinically meaningful and statistically significant reduction in proteinuria, a surrogate marker which correlates to progression to kidney failure.
Accelerated approval from the FDA allows for drugs that treat a serious condition with an unmet medical need to be approved using surrogate endpoints, or an indirect marker believed to predict a clinical effect.
Fabhalta received FDA approval in December 2023 to treat adults with the rare blood disorder paroxysmal nocturnal hemoglobinuria.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
April 15, 2024 14:40 ET (18:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations